your initial deposit *subject to change and depends on individual circumstances.
Silence Therapeutics plc (LSE: SLN) is a global leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases.
The company possesses one of the world’s most comprehensive RNAi therapeutic platforms comprised of proprietary delivery technologies, potent siRNA...Read more
Silence Therapeutics promotes Sedgwick to CEO role; Christély resignsFebruary 10 2012, 7:29am
Gene silencing specialist Silence Therapeutics (LON:SLN) announced today that Tony Sedgwick has been appointed the new CEO of the company following the resignation of Thomas Christély.
Sedgwick was formerly the chief business officer and his promotion takes effect immediately, the firm said.
Christély has resigned as a director for personal reasons but will ensure a smooth transition, the company added.
The company's chairman Jerry Randall said: "Tony has a great deal of relevant experience gained from the global pharmaceutical industry. He has made a very positive impact on Silence since joining in September last year and has demonstrated the right leadership skills needed as the company continues to gain momentum."
He thanked Christély for his many years of valuable service, on behalf of the board, and wished him well for the future.
New chief executive Sedgwick said that since joining the company, he had been excited about the opportunities ahead.
"We have already strengthened the business development team with the appointment of Dr Georg Buchner who will now take full responsibility for business development.
"The company's pipeline including Atu027 is making good progress and is endorsed by external partners," he said.
He added that in the next few years, he planned to increase the commercial focus of the company.
The company develops siRNAs, which are double-stranded molecules that silence certain genes. These are being developed to be used in targeting multiple disease types, including cancer.
Last month, the company announced a collaboration agreement with
US–based firm miRagen to assess delivery methods for new, micro versions of gene silencing technology to treat serious diseases.